Trials / Completed
CompletedNCT00738855
Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO)
Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO).
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Mansoura University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Mini abstract : Altogether 100 patients with 117 episodes of ASBO were randomized into control and gastrografin groups. Eight episodes in eight patients were excluded. Gastrografin group showed a significant decrease of both the time between admission and operation and that of hospital stay .The need for surgery was reduced but statistically insignificant.
Detailed description
Abstract Background: Many published studies have shown that Gastrografin can be used for diagnosis post operative acute small bowel obstruction (ASBO) and assessing the need for surgical intervention .However,the studies have reported conflicting results hence the aim of our study to test this hypothesis. Patients and methods : Altogether 100 patients with 117 episodes of ASBO were randomized into control and gastrografin groups in a double blinded fashion. Eight episodes in eight patients were excluded due to protocol violation. In Gastrografin group,100 ml of the dye administered through a nasogastric tube and complete obstruction has been considered if the contrast failed to reach the colon on the 24-hour film. Patients were operated on only if they developed signs of strangulation or failed to improve within 48 hours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Oral Gastrografin | 100 ml of the dye administered through a nasogastric tube |
| OTHER | Nothing per os | A nasogastric tube |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2008-08-21
- Last updated
- 2008-11-26
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT00738855. Inclusion in this directory is not an endorsement.